Details of the Drug Combinations

General Information of This Drug (ID: DMK1IPV)

Drug Name

Ibrexafungerp DMK1IPV

Synonyms

SCY-078

Indication

Disease Entry	ICD 11	Status	REF
Vulvovaginal Candidiasis	1F23.10	Approved	[1]
Invasive candidiasis	1F23	Phase 3	[2]
Fungal infection	1F29-1F2F	Phase 2	[3]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Voriconazole + SCY-078	DCNCFP6	Voriconazole	Invasive Pulmonary Aspergillosis	[4]
Caspofungin + SCY-078	DCE2X0G	Caspofungin	Candidiasis, Invasive	[5]
SCY-078 + Fluconazole	DC84E2P	Fluconazole	Recurrent Vulvovaginal Candidiasis	[6]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214900.
2	ClinicalTrials.gov (NCT03059992) Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI). U.S. National Institutes of Health.
3	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031918)
4	ClinicalTrials.gov (NCT03672292) Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
5	ClinicalTrials.gov (NCT05178862) A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
6	ClinicalTrials.gov (NCT04029116) Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)